Clinical Research Directory

Inclusion Criteria: * Met HLH-2004 diagnostic criteria; * EBV-DNA in the peripheral blood \> 1000 copies/ml or EBV-encoded small RNA (EBER) detected in tissues; * Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues; * Age \>18 years old, gender is not limited; * Estimated survival time \> 1 month; * Informed consent obtained. Exclusion Criteria: * Active infections (viral, bacterial, fungal or parasitic); * Diagosed with malignant tumos within 5 years； * Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery; * Heart function above grade II (NYHA); * Severe myocardial injury：TNT、TNI、CK-MB \> 3 ULN; * Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease; * Pregnancy or lactating Women; * Allergic to pegylated liposomal doxorubicin and etoposide; * HIV antibody positivity; * Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable); * Participate in other clinical research at the same time; * The researchers considered that patients are not suitable for the study.